BioWorld

Jan. 31, 2002

Amylin Seeks $92M Publicly To Fund AC2993 Phase IIIs

Amylin Pharmaceuticals Inc. started the second of three Phase III trials on AC2993, a compound designed to treat people with Type II diabetes by improving glucose control. (BioWorld Today) Read More

Signature Continues Acquisitions, Buys PDL’s Small-Molecule Unit

Signature BioScience Inc. is moving toward drug discovery and fueling the trek with acquisitions. (BioWorld Today) Read More

Scar Tissue In Injured Spinal Cord Acts As Barrier Preventing Normal Regeneration, Functional Recovery

IntraBiotics Netting $13.9M From Private Deal For Iseganan Studies

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 8, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...

Woman taking medication for mental illness

Autobahn on the fast track with bipolar thyroid agonist

BioWorld

Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...